4-[6-(4-trifluoromethylphenyl)pyrimidin-4-yloxy]benzothiazol-2-ylamine | 659730-31-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 4-[6-(4-trifluoromethylphenyl)pyrimidin-4-yloxy]benzothiazol-2-ylamine
• 英文别名: 4-[6-(4-Trifluoromethyl-phenyl)-pyrimidin-4-yloxy]-benzothiazol-2-ylamine；4-[6-[4-(trifluoromethyl)phenyl]pyrimidin-4-yl]oxy-1,3-benzothiazol-2-amine
• CAS: 659730-31-1
• 化学式: C₁₈H₁₁F₃N₄OS
• 分子量: 388.373
• InChiKey: IUSOBMHCOYGJSN-UHFFFAOYSA-N

物化性质

• 沸点：
  550.2±60.0 °C(Predicted)
• 密度：
  1.469±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.7
• 重原子数：
  27
• 可旋转键数：
  3
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.06
• 拓扑面积：
  102
• 氢给体数：
  1
• 氢受体数：
  9

反应信息

• 作为反应物：
  描述：

  4-[6-(4-trifluoromethylphenyl)pyrimidin-4-yloxy]benzothiazol-2-ylamine 生成 N-[4-[[6-[4-(三氟甲基)苯基]-4-嘧啶基]氧基]-2-苯并噻唑基]乙酰胺
  参考文献：
  名称：

  [EN] VANILLOID RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS
  [FR] LIGANDS DE RECEPTEUR VANILLOIDE ET LEUR UTILISATION DANS DES TRAITEMENTS

  摘要：

  含有通用结构和组成的化合物及其组合物，用于治疗急性、炎症性和神经痛、牙痛、普通头痛、偏头痛、集群性头痛、混合性血管和非血管综合症、紧张性头痛、普通炎症、关节炎、风湿性疾病、骨关节炎、炎症性肠病、炎症性眼病、炎症性或不稳定的膀胱疾病、牛皮癣、带有炎症成分的皮肤病、慢性炎症状况、炎症性疼痛及相关的高敏性和触痛，神经痛及相关的高敏性和触痛、糖尿病神经病疼痛、烧伤后神经痛、交感神经维持的疼痛、去神经症候群、哮喘、上皮组织损伤或功能障碍、单纯疱疹、呼吸道、泌尿生殖系统、胃肠道或血管区域的内脏运动障碍、伤口、烧伤、过敏性皮肤反应、瘙痒、白癜风、普通胃肠疾病、胃溃疡、十二指肠溃疡、腹泻、坏死性剂引起的胃病变、毛发生长、血管运动或过敏性鼻炎、支气管疾病或膀胱疾病。

  公开号：

  WO2004014871A1
• 作为产物：
  描述：

  4-氯-6-(4-(三氟甲基)苯基)嘧啶 、 4-羟基-2-氨基苯并噻唑 在 4-羟基-2-氨基苯并噻唑 作用下， 生成 4-[6-(4-trifluoromethylphenyl)pyrimidin-4-yloxy]benzothiazol-2-ylamine
  参考文献：
  名称：

  [EN] VANILLOID RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS
  [FR] LIGANDS DE RECEPTEUR VANILLOIDE ET LEUR UTILISATION DANS DES TRAITEMENTS

  摘要：

  含有通用结构和组成的化合物及其组合物，用于治疗急性、炎症性和神经痛、牙痛、普通头痛、偏头痛、集群性头痛、混合性血管和非血管综合症、紧张性头痛、普通炎症、关节炎、风湿性疾病、骨关节炎、炎症性肠病、炎症性眼病、炎症性或不稳定的膀胱疾病、牛皮癣、带有炎症成分的皮肤病、慢性炎症状况、炎症性疼痛及相关的高敏性和触痛，神经痛及相关的高敏性和触痛、糖尿病神经病疼痛、烧伤后神经痛、交感神经维持的疼痛、去神经症候群、哮喘、上皮组织损伤或功能障碍、单纯疱疹、呼吸道、泌尿生殖系统、胃肠道或血管区域的内脏运动障碍、伤口、烧伤、过敏性皮肤反应、瘙痒、白癜风、普通胃肠疾病、胃溃疡、十二指肠溃疡、腹泻、坏死性剂引起的胃病变、毛发生长、血管运动或过敏性鼻炎、支气管疾病或膀胱疾病。

  公开号：

  WO2004014871A1

文献信息

• Vanilloid receptor ligands and their use in treatments
  申请人：——

  公开号：US20040082780A1

  公开（公告）日：2004-04-29

  Compounds having the general structure 1 and compositions containing them, for the treatment of acute, inflammatory and neuropathic pain, dental pain, general headache, migraine, cluster headache, mixed-vascular and non-vascular syndromes, tension headache, general inflammation, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, inflammatory eye disorders, inflammatory or unstable bladder disorders, psoriasis, skin complaints with inflammatory components, chronic inflammatory conditions, inflammatory pain and associated hyperalgesia and allodynia, neuropathic pain and associated hyperalgesia and allodynia, diabetic neuropathy pain, causalgia, sympathetically maintained pain, deafferentation syndromes, asthma, epithelial tissue damage or dysfunction, herpes simplex, disturbances of visceral motility at respiratory, genitourinary, gastrointestinal or vascular regions, wounds, burns, allergic skin reactions, pruritus, vitiligo, general gastrointestinal disorders, gastric ulceration, duodenal ulcers, diarrhea, gastric lesions induced by necrotising agents, hair growth, vasomotor or allergic rhinitis, bronchial disorders or bladder disorders.

  具有一般结构1的化合物及其组成物，用于治疗急性、炎症和神经痛、牙痛、普通头痛、偏头痛、集群头痛、混合血管和非血管综合症、紧张性头痛、普通炎症、关节炎、风湿性疾病、骨关节炎、炎症性肠病、炎症性眼疾、炎症性或不稳定的膀胱疾病、牛皮癣、具有炎症成分的皮肤病、慢性炎症状况、炎症性疼痛及相关的高敏感性和触痛、神经痛及相关的高敏感性和触痛、糖尿病神经病痛、烧灼性疼痛、交感神经维持性疼痛、去神经症候群、哮喘、上皮组织损伤或功能障碍、单纯疱疹、呼吸、泌尿、胃肠或血管区域的内脏运动障碍、伤口、烧伤、过敏性皮肤反应、瘙痒、白癜风、普通胃肠障碍、胃溃疡、十二指肠溃疡、腹泻、坏死剂诱导的胃病变、毛发生长、血管运动或过敏性鼻炎、支气管疾病或膀胱疾病。
• Pyridazine derivatives useful as vanilloid receptor ligands
  申请人：Amgen, Inc

  公开号：EP2270006A1

  公开（公告）日：2011-01-05

  Compounds having the general structure and compositions containing them, for the treatment of acute, inflammatory and neuropathic pain, dental pain, general headache, migraine, cluster headache, mixed-vascular and non-vascular syndromes, tension headache, general inflammation, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, inflammatory eye disorders, inflammatory or unstable bladder disorders, psoriasis, skin complaints with inflammatory components, chronic inflammatory conditions, inflammatory pain and associated hyperalgesia and allodynia, neuropathic pain and associated hyperalgesia and allodynia, diabetic neuropathy pain, causalgia, sympathetically maintained pain, deafferentation syndromes, asthma, epithelial tissue damage or dysfunction, herpes simplex, disturbances of visceral motility at respiratory, genitourinary, gastrointestinal or vascular regions, wounds, burns, allergic skin reactions, pruritus, vitiligo, general gastrointestinal disorders, gastric ulceration, duodenal ulcers, diarrhea, gastric lesions induced by necrotising agents, hair growth, vasomotor or allergic rhinitis, bronchial disorders or bladder disorders. or any pharmaceutically-acceptable salt thereof, wherein: J is O or S; X is = C(R2); Y is N;

  具有一般结构的化合物和含有这些化合物的组合物，用于治疗急性、炎症性和神经性疼痛、牙痛、一般头痛、偏头痛、丛集性头痛、混合血管性和非血管性综合征、紧张性头痛、一般炎症、关节炎、风湿性疾病、骨关节炎、炎症性肠道疾病、炎症性眼部疾病、炎症性或不稳定的膀胱疾病、银屑病、含有炎症成分的皮肤不适、慢性炎症、炎症性疼痛及相关的痛觉减退和痛觉过敏、神经性疼痛及相关的痛觉减退和痛觉过敏、糖尿病神经病变性疼痛、因痛症、交感神经维持性疼痛、去感觉综合征、哮喘、上皮组织损伤或功能障碍、单纯疱疹、呼吸道、泌尿生殖道、胃肠道或血管内脏运动障碍、伤口、烧伤、皮肤过敏反应、瘙痒症、白癜风、一般胃肠道疾病、胃溃疡、十二指肠溃疡、腹泻、坏死剂引起的胃部病变、毛发生长、血管运动性或过敏性鼻炎、支气管疾病或膀胱疾病。 或其任何药学上可接受的盐，其中 J 是 O 或 S； X 是 = C(R2) Y 是 N；
• Novel Vanilloid Receptor-1 Antagonists:  2. Structure−Activity Relationships of 4-Oxopyrimidines Leading to the Selection of a Clinical Candidate
  作者：Elizabeth M. Doherty、Christopher Fotsch、Anthony W. Bannon、Yunxin Bo、Ning Chen、Celia Dominguez、James Falsey、Narender R. Gavva、Jodie Katon、Thomas Nixey、Vassil I. Ognyanov、Liping Pettus、Robert M. Rzasa、Markian Stec、Sekhar Surapaneni、Rami Tamir、Jiawang Zhu、James J. S. Treanor、Mark H. Norman

  DOI：10.1021/jm070190p

  日期：2007.7.1

  A series of novel 4-oxopyrimidine TRPV1 antagonists was evaluated in assays measuring the blockade of capsaicin or acid-induced influx of calcium into CHO cells expressing TRPV1. The investigation of the structure-activity relationships in the heterocyclic A-region revealed the optimum pharmacophoric elements required for activity in this series and resulted in the identification of subnanomolar TRPV1 antagonists. The most potent of these antagonists were thoroughly profiled in pharmacokinetic assays. Optimization of the heterocyclic A-region led to the design and synthesis of 23, a compound that potently blocked multiple modes of TRPV1 activation. Compound 23 was shown to be effective in a rodent "on-target" biochemical challenge model (capsaicin-induced flinch, ED50 = 0.33 mg/kg p.o.) and was antihyperalgesic in a model of inflammatory pain (CFA-induced thermal hyperalgesia, MED = 0.83 mg/kg, p.o.). Based on its in vivo efficacy and pharmacokinetic profile, compound 23 (N-4-[6-(4-trifluoromethyl-phenyl)-pyrimidin-4-yloxy]-benzothiazol-2-yl}-acetamide; AMG 517) was selected for further evaluation in human clinical trials.
• VANILLOID RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS
  申请人：Amgen Inc.

  公开号：EP1546116A1

  公开（公告）日：2005-06-29
• US7144888B2
  申请人：——

  公开号：US7144888B2

  公开（公告）日：2006-12-05